Needham & Company Upgrades ResMed (RMD) to Buy
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $224.46 -1.01%
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company analyst Mike Matson upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $180.00.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $153.89 yesterday.
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- UBS Upgrades Pagegroup Plc. (PAGE:LN) (MPGPY) to Buy
- ResMed (RMD:AU) (RMD) PT Raised to AUD36.50 at JPMorgan
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
